In a report released yesterday, Daniel Clark from Leerink Partners maintained a Buy rating on Zoetis (ZTS – Research Report), with a price target of $205.00. Discover outperforming stocks and ...

Parsippany, New Jersey-based Zoetis Inc. (ZTS) discovers, develops, and commercializes animal health medicines, vaccines, and diagnostic products and services. With a market cap of $75.4 billion ...

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Leerink Partners analyst Daniel Clark reiterated a Buy rating on Zoetis (ZTS – Research Report) on January 13 and set a price target of $215.00. Discover outperforming stocks and invest smarter ...

Zoetis (ZTS) closed at $165.02 in the latest trading session, marking a +0.94% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.16% for the day. Elsewhere, the ...

As of 12:35:37 PM EST. Market Open.

Sorry, Hollywood. Indie studios have officially taken over the poster game. Of the 25 films listed below, I can count the number of legacy studios on one hand (even ...

After hours: January 24 at 7:01:13 p.m. EST ...